ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 131,41
0,69%
Dow Jones
39 056,39
0,44%
DAX
18 498,38
0,32%
Brent Oil
83,575
0,86%
Bitcoin
62 064,13
-0,43%
Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Cellectis SA (CLLS)

  7. Cellectis SA (CLLS) Actualités

CLLS Cellectis SA

3,0937
-0,0063 (-0,20%)
Dernière mise à jour : 21:54:32
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Cellectis SA CLLS NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
-0,0063 -0,20% 3,0937 21:54:32
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
3,00 3,00 3,16 3,10
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
06/5/202412:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
06/5/202408:00GLOBECellectis Announces Completion of the Additional Equity..
02/5/202422:30GLOBECellectis Appoints Arthur Stril as Interim Chief Financial..
29/4/202422:46GLOBECellectis Reports Financial Results for the Fourth Quarter..
22/4/202422:30GLOBECellectis Presents Novel TALEN® Editing Processes Enabling..
10/4/202422:30GLOBECellectis Publishes a Novel Intronic Gene Editing Approach..
08/4/202422:30GLOBECellectis Announces Two Poster Presentations on Novel TALEN®..
16/1/202422:45EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
16/1/202422:30GLOBECellectis announces the drawdown of the second tranche of..
22/12/202322:35EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
22/12/202322:30GLOBECellectis Reports Results from Shareholders Meeting Held on..
22/12/202322:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
05/12/202322:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
17/11/202322:56EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
17/11/202322:35EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
17/11/202322:30GLOBECellectis’ Shareholders Meeting to be Held on December 22,..
15/11/202313:48EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
15/11/202308:30GLOBECellectis Announces the execution of the Subsequent..
09/11/202322:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
06/11/202322:35EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
06/11/202322:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
06/11/202322:30GLOBECellectis Reports Financial Results for Third Quarter and..
02/11/202321:35EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
02/11/202321:30GLOBECellectis to Present Preliminary Results of NATHALI_01 and..
01/11/202321:35EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
01/11/202321:30GLOBECellectis to Report Third Quarter 2023 Financial Results on..
01/11/202320:15APSBiotech Shares Soar After AstraZeneca Stake & Research..
01/11/202312:52DJNCellectis Shares Soar Premarket on AstraZeneca Deal
01/11/202312:51DJNCellectis Shares Soar Premarket on AstraZeneca Deal
01/11/202311:44EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
01/11/202309:17DJNAstraZeneca to Invest $245 Million in Deal With Cellectis
01/11/202308:00GLOBECellectis Announces Strategic Collaboration and Investment..
31/10/202322:10EDGAR2Form 20-F/A - Annual and transition report of foreign..
31/10/202322:09EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
31/10/202321:35EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
31/10/202321:30GLOBECellectis Presents Pre-Clinical Data on Multi-armored..
24/10/202322:35EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
12/10/202322:35EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
12/10/202322:30GLOBECellectis and Imagine Institute Publish A Proof-Of-Concept..
27/9/202322:35EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
27/9/202322:30GLOBECellectis to Present Pre-Clinical Data on Multi-armored..
05/9/202322:32EDGAR2Form 6-K/A - Report of foreign issuer [Rules 13a-16 and..
07/8/202323:05EDGAR2Form S-8 - Securities to be offered to employees in employee..
07/8/202322:35EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
07/8/202322:30GLOBECellectis Provides Full Report for Second Quarter 2023..
07/8/202322:17EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
03/8/202322:35EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
03/8/202322:30GLOBECellectis Provides Business Updates and Preliminary..
27/7/202322:35EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
27/7/202322:30GLOBECellectis to Report Second Quarter 2023 Financial Results on..

Dernières Valeurs Consultées

NASDAQ
CLLS
Cellectis
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés